[Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
The study included 62 patients (30 males and 32 females, age 19-80 years, duration of the disease 2-28 years) with vertebrogenic disease suffering from urgent, frequent voiding. All the patients have undergone detailed urodynamic and general urological examination monthly before and after treatment. Spasmex was given orally to 16 patients of group 1 (15 mg/day), 24 patients of group 2 (30 mg/day) and 22 patients of group 3 (45 mg/day) once a day for 6 months. It is shown that spasmex in doses 15, 30 and 45 mg was highly effective and well tolerated. Spasmex in a dose 45 mg/day not only significantly reduced the number of urinations but also increased cystometric capacity and mean effective volume of the bladder, reduced the number of urgent voiding. Main side effects of the drug were xerostomia and constipation the frequency of which was the same in all the groups.
Mazo
E B
EB
Babanina
G A
GA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001561:Benzilates; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009662:Nortropanes / Q000008:administration & dosage / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D013118:Spinal Cord Diseases / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
D001561:Benzilates; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride